Observations placeholder
Zelboraf
Identifier
020394
Type of Spiritual Experience
Number of hallucinations: 4
Background
A description of the experience
Vemurafenib (INN, marketed as Zelboraf) is a B-Raf enzyme inhibitor developed for the treatment of late-stage melanoma. The name "vemurafenib" comes from V600E mutated BRAF inhibition.
Side effects
At the maximum tolerated dose (MTD) of 960 mg twice a day 31% of patients get skin lesions that may need surgical removal. The BRIM-2 trial investigated 132 patients; the most common adverse events were arthralgia in 58% of patients, skin rash in 52%, and photosensitivity in 52%. In order to better manage side effects some form of dose modification was necessary in 45% of patients. The median daily dose was 1750 mg, which is 91% of the MTD.
On Feb, 9, 2016: 1,271 people reported to have side effects when taking Zelboraf. Among them, 4 people (0.16%) have Hallucination.
On Jan, 28, 2016: 1,271 people reported to have side effects when taking Zelboraf. Among them, 310 people (24.39%) have Death.
Time on Zelboraf when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 23.08% | 76.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Zelboraf :
| Female | Male | |
| Death | 36.07% | 63.93% |
Age of people who have Death when taking Zelboraf :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.00% | 0.00% | 4.17% | 6.94% | 31.94% | 56.94% |
Top conditions involved for these people :
- Malignant melanoma (70 people, 22.58%)
- Bone neoplasm malignant (11 people, 3.55%)
- Metastases to lung (10 people, 3.23%)